ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
66 889,88
-0,28%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Panbela Therapeutics Inc (PBLA)

  7. Panbela Therapeutics Inc (PBLA) Actualités

PBLA

Panbela Therapeutics (PBLA)

Panbela Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PBLA
DateHeureSourceTitreSymboleSociété
15/05/202422h10GlobeNewswire Inc.Panbela Provides Business Update and Reports Q1 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
06/05/202414h00GlobeNewswire Inc.Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacNASDAQ:PBLAPanbela Therapeutics Inc
01/05/202422h15GlobeNewswire Inc.Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024NASDAQ:PBLAPanbela Therapeutics Inc
30/04/202414h00GlobeNewswire Inc.Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekNASDAQ:PBLAPanbela Therapeutics Inc
26/04/202422h39Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202422h36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202422h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202415h09Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:PBLAPanbela Therapeutics Inc
22/04/202414h00GlobeNewswire Inc.Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025NASDAQ:PBLAPanbela Therapeutics Inc
18/04/202422h31Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PBLAPanbela Therapeutics Inc
18/04/202414h00GlobeNewswire Inc.Panbela Announces Poster Presentation at American Association for Cancer Research:NASDAQ:PBLAPanbela Therapeutics Inc
17/04/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PBLAPanbela Therapeutics Inc
16/04/202423h29GlobeNewswire Inc.Panbela Announces Transfer to OTCQB MarketNASDAQ:PBLAPanbela Therapeutics Inc
04/04/202422h17Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PBLAPanbela Therapeutics Inc
29/03/202422h08Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PBLAPanbela Therapeutics Inc
26/03/202421h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PBLAPanbela Therapeutics Inc
26/03/202421h10GlobeNewswire Inc.Panbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
26/03/202412h21IH Market NewsU.S. Index Futures on the Rise, Oil Prices Show StabilityNASDAQ:PBLAPanbela Therapeutics Inc
25/03/202421h15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:PBLAPanbela Therapeutics Inc
12/03/202421h15GlobeNewswire Inc.Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024NASDAQ:PBLAPanbela Therapeutics Inc
15/02/202414h00GlobeNewswire Inc.Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares RequirementsNASDAQ:PBLAPanbela Therapeutics Inc
14/02/202402h10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PBLAPanbela Therapeutics Inc
01/02/202413h00GlobeNewswire Inc.Panbela Announces Closing of Approximately $9.0 Million Public OfferingNASDAQ:PBLAPanbela Therapeutics Inc
30/01/202423h28Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:PBLAPanbela Therapeutics Inc
30/01/202414h15GlobeNewswire Inc.Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)NASDAQ:PBLAPanbela Therapeutics Inc
29/01/202412h15GlobeNewswire Inc.Panbela Announces Pricing of Approximately $9.0 Million Public OfferingNASDAQ:PBLAPanbela Therapeutics Inc
25/01/202418h22Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PBLAPanbela Therapeutics Inc
25/01/202413h00GlobeNewswire Inc.Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated MomentumNASDAQ:PBLAPanbela Therapeutics Inc
18/01/202414h15GlobeNewswire Inc.Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialNASDAQ:PBLAPanbela Therapeutics Inc
16/01/202414h00GlobeNewswire Inc.Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024NASDAQ:PBLAPanbela Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PBLA

Dernières Valeurs Consultées

NASDAQ
UG
United Guardian
BOV
GFSA1
GAFISA ON
NASDAQ
JSPRW
Jasper Therapeutics
NYSE
CIM
Chimera Investment
EU
SIFG
Sif Holding NV
BOV
GPTW11
Great Place to Work
BOV
GFSA11
GAFISA ON
EU
VASTB
VASTNED
EU
QFG
Quest For Growth NV
COIN
SOLUSD
Solana
BOV
GGPS3
GPS Participacoes e Empr... ON
EU
R214S
R214S
EU
H915S
H915S
LSE
REL
Relx
ASX
SFR
Sandfire Resources
NASDAQ
OPRT
Oportun Financial
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés